Long-term follow-up of symptomatic HIV-infected patients originally randomized to early versus later zidovudine treatment: Report of a Veterans Affairs Cooperative Study

Michael S. Simberkoff, Pamela M. Hartigan, John D. Hamilton, Philip L. Day, Gigi R. Diamond, Gordon Dickinson, George L. Drusano, Merrill J. Egorin, W. Lance George, Fred M. Gordin, Clifton A. Hawkes, Peter C. Jensen, Nancy G. Klimas, Ann M. Labriola, Christopher J. Lahart, William A. O'Brien, Charles N. Oster, Kent J. Weinhold, Nelda P. Wray, Susan B. Zolla Pazner

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Following a 4-year controlled trial comparing early and later zidovudine treatment, we conducted an additional 3-year follow-up. Of the original 338 patients, 275 participated. Clinical outcome measures were AIDS and death. In the early therapy group (n = 170), 67 patients progressed to AIDS compared with 85 in the later therapy group (n = 168); the relative risk (RR) comparing early with later therapy was 0.72 (95% confidence interval [CI] 0.52-0.99; p = 0.044). The early therapy group had 74 deaths compared with 73 in the later therapy (RR = 0.98: 95% CI, 0.71-1.36; p = 0.91). The early group had a peak CD4+ count increase at 1-2 months and a delay of 1 year before CD4+ counts fell below baseline. For patients who received zidovudine for more than the median duration (20.3 months) before their first AIDS diagnosis, the RR for death was 2.08 (95% CI, 1.36-3.19, p = 0.001). Additional factors independently associated with poor prognosis following AIDS were a CD4+ count of <100 cells/mm3 and increased severity of the first AIDS diagnosis, whereas use of another antiretroviral agent was associated with improved survival. We conclude that early zidovudine therapy delays progression to AIDS but does not affect survival. Patients who progress to AIDS while on prolonged zidovudine monotherapy many benefit from a change to other antiretroviral therapy(ies).

Original languageEnglish
Pages (from-to)142-150
Number of pages9
JournalJournal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Volume11
Issue number2
StatePublished - Feb 8 1996
Externally publishedYes

Fingerprint

Zidovudine
Veterans
Acquired Immunodeficiency Syndrome
HIV
CD4 Lymphocyte Count
Secondary Prevention
Confidence Intervals
Therapeutics
Anti-Retroviral Agents
Survival
Group Psychotherapy
Outcome Assessment (Health Care)

Keywords

  • Human immunodeficiency virus
  • Opportunistic infections
  • Survival
  • Zidovudine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Virology

Cite this

Long-term follow-up of symptomatic HIV-infected patients originally randomized to early versus later zidovudine treatment : Report of a Veterans Affairs Cooperative Study. / Simberkoff, Michael S.; Hartigan, Pamela M.; Hamilton, John D.; Day, Philip L.; Diamond, Gigi R.; Dickinson, Gordon; Drusano, George L.; Egorin, Merrill J.; Lance George, W.; Gordin, Fred M.; Hawkes, Clifton A.; Jensen, Peter C.; Klimas, Nancy G.; Labriola, Ann M.; Lahart, Christopher J.; O'Brien, William A.; Oster, Charles N.; Weinhold, Kent J.; Wray, Nelda P.; Zolla Pazner, Susan B.

In: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, Vol. 11, No. 2, 08.02.1996, p. 142-150.

Research output: Contribution to journalArticle

Simberkoff, MS, Hartigan, PM, Hamilton, JD, Day, PL, Diamond, GR, Dickinson, G, Drusano, GL, Egorin, MJ, Lance George, W, Gordin, FM, Hawkes, CA, Jensen, PC, Klimas, NG, Labriola, AM, Lahart, CJ, O'Brien, WA, Oster, CN, Weinhold, KJ, Wray, NP & Zolla Pazner, SB 1996, 'Long-term follow-up of symptomatic HIV-infected patients originally randomized to early versus later zidovudine treatment: Report of a Veterans Affairs Cooperative Study', Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, vol. 11, no. 2, pp. 142-150.
Simberkoff, Michael S. ; Hartigan, Pamela M. ; Hamilton, John D. ; Day, Philip L. ; Diamond, Gigi R. ; Dickinson, Gordon ; Drusano, George L. ; Egorin, Merrill J. ; Lance George, W. ; Gordin, Fred M. ; Hawkes, Clifton A. ; Jensen, Peter C. ; Klimas, Nancy G. ; Labriola, Ann M. ; Lahart, Christopher J. ; O'Brien, William A. ; Oster, Charles N. ; Weinhold, Kent J. ; Wray, Nelda P. ; Zolla Pazner, Susan B. / Long-term follow-up of symptomatic HIV-infected patients originally randomized to early versus later zidovudine treatment : Report of a Veterans Affairs Cooperative Study. In: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 1996 ; Vol. 11, No. 2. pp. 142-150.
@article{c45ec95f35d941dabd7a629c2178cb4c,
title = "Long-term follow-up of symptomatic HIV-infected patients originally randomized to early versus later zidovudine treatment: Report of a Veterans Affairs Cooperative Study",
abstract = "Following a 4-year controlled trial comparing early and later zidovudine treatment, we conducted an additional 3-year follow-up. Of the original 338 patients, 275 participated. Clinical outcome measures were AIDS and death. In the early therapy group (n = 170), 67 patients progressed to AIDS compared with 85 in the later therapy group (n = 168); the relative risk (RR) comparing early with later therapy was 0.72 (95{\%} confidence interval [CI] 0.52-0.99; p = 0.044). The early therapy group had 74 deaths compared with 73 in the later therapy (RR = 0.98: 95{\%} CI, 0.71-1.36; p = 0.91). The early group had a peak CD4+ count increase at 1-2 months and a delay of 1 year before CD4+ counts fell below baseline. For patients who received zidovudine for more than the median duration (20.3 months) before their first AIDS diagnosis, the RR for death was 2.08 (95{\%} CI, 1.36-3.19, p = 0.001). Additional factors independently associated with poor prognosis following AIDS were a CD4+ count of <100 cells/mm3 and increased severity of the first AIDS diagnosis, whereas use of another antiretroviral agent was associated with improved survival. We conclude that early zidovudine therapy delays progression to AIDS but does not affect survival. Patients who progress to AIDS while on prolonged zidovudine monotherapy many benefit from a change to other antiretroviral therapy(ies).",
keywords = "Human immunodeficiency virus, Opportunistic infections, Survival, Zidovudine",
author = "Simberkoff, {Michael S.} and Hartigan, {Pamela M.} and Hamilton, {John D.} and Day, {Philip L.} and Diamond, {Gigi R.} and Gordon Dickinson and Drusano, {George L.} and Egorin, {Merrill J.} and {Lance George}, W. and Gordin, {Fred M.} and Hawkes, {Clifton A.} and Jensen, {Peter C.} and Klimas, {Nancy G.} and Labriola, {Ann M.} and Lahart, {Christopher J.} and O'Brien, {William A.} and Oster, {Charles N.} and Weinhold, {Kent J.} and Wray, {Nelda P.} and {Zolla Pazner}, {Susan B.}",
year = "1996",
month = "2",
day = "8",
language = "English",
volume = "11",
pages = "142--150",
journal = "Journal of acquired immune deficiency syndromes (1999)",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "2",

}

TY - JOUR

T1 - Long-term follow-up of symptomatic HIV-infected patients originally randomized to early versus later zidovudine treatment

T2 - Report of a Veterans Affairs Cooperative Study

AU - Simberkoff, Michael S.

AU - Hartigan, Pamela M.

AU - Hamilton, John D.

AU - Day, Philip L.

AU - Diamond, Gigi R.

AU - Dickinson, Gordon

AU - Drusano, George L.

AU - Egorin, Merrill J.

AU - Lance George, W.

AU - Gordin, Fred M.

AU - Hawkes, Clifton A.

AU - Jensen, Peter C.

AU - Klimas, Nancy G.

AU - Labriola, Ann M.

AU - Lahart, Christopher J.

AU - O'Brien, William A.

AU - Oster, Charles N.

AU - Weinhold, Kent J.

AU - Wray, Nelda P.

AU - Zolla Pazner, Susan B.

PY - 1996/2/8

Y1 - 1996/2/8

N2 - Following a 4-year controlled trial comparing early and later zidovudine treatment, we conducted an additional 3-year follow-up. Of the original 338 patients, 275 participated. Clinical outcome measures were AIDS and death. In the early therapy group (n = 170), 67 patients progressed to AIDS compared with 85 in the later therapy group (n = 168); the relative risk (RR) comparing early with later therapy was 0.72 (95% confidence interval [CI] 0.52-0.99; p = 0.044). The early therapy group had 74 deaths compared with 73 in the later therapy (RR = 0.98: 95% CI, 0.71-1.36; p = 0.91). The early group had a peak CD4+ count increase at 1-2 months and a delay of 1 year before CD4+ counts fell below baseline. For patients who received zidovudine for more than the median duration (20.3 months) before their first AIDS diagnosis, the RR for death was 2.08 (95% CI, 1.36-3.19, p = 0.001). Additional factors independently associated with poor prognosis following AIDS were a CD4+ count of <100 cells/mm3 and increased severity of the first AIDS diagnosis, whereas use of another antiretroviral agent was associated with improved survival. We conclude that early zidovudine therapy delays progression to AIDS but does not affect survival. Patients who progress to AIDS while on prolonged zidovudine monotherapy many benefit from a change to other antiretroviral therapy(ies).

AB - Following a 4-year controlled trial comparing early and later zidovudine treatment, we conducted an additional 3-year follow-up. Of the original 338 patients, 275 participated. Clinical outcome measures were AIDS and death. In the early therapy group (n = 170), 67 patients progressed to AIDS compared with 85 in the later therapy group (n = 168); the relative risk (RR) comparing early with later therapy was 0.72 (95% confidence interval [CI] 0.52-0.99; p = 0.044). The early therapy group had 74 deaths compared with 73 in the later therapy (RR = 0.98: 95% CI, 0.71-1.36; p = 0.91). The early group had a peak CD4+ count increase at 1-2 months and a delay of 1 year before CD4+ counts fell below baseline. For patients who received zidovudine for more than the median duration (20.3 months) before their first AIDS diagnosis, the RR for death was 2.08 (95% CI, 1.36-3.19, p = 0.001). Additional factors independently associated with poor prognosis following AIDS were a CD4+ count of <100 cells/mm3 and increased severity of the first AIDS diagnosis, whereas use of another antiretroviral agent was associated with improved survival. We conclude that early zidovudine therapy delays progression to AIDS but does not affect survival. Patients who progress to AIDS while on prolonged zidovudine monotherapy many benefit from a change to other antiretroviral therapy(ies).

KW - Human immunodeficiency virus

KW - Opportunistic infections

KW - Survival

KW - Zidovudine

UR - http://www.scopus.com/inward/record.url?scp=1842458302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842458302&partnerID=8YFLogxK

M3 - Article

C2 - 8556396

AN - SCOPUS:1842458302

VL - 11

SP - 142

EP - 150

JO - Journal of acquired immune deficiency syndromes (1999)

JF - Journal of acquired immune deficiency syndromes (1999)

SN - 1525-4135

IS - 2

ER -